Welcome to
ERYTECH Pharma
Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.
ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
news
ERYTECH Pharma receives FDA IND clearance to initiate a clinical study in Acute Lymphoblastic Leukemia in the U.S.
GRASPA® (ERY-ASP) receives Orphan Drug Designation for Acute Myeloïd Leukemia from the European Medicine Agency (EMA).
ERYTECH Pharma announces it received the authorization from ANSM (French Medicine Agency) to begin a Phase II B clinical trial in Acute Myeloïd Leukemia with GRASPA® (ERY-ASP)
diary
ERYTECH Pharma attends 11th MIDCAP Santé Forum which takes place on Thursday May 23rd at Chateauform’ Monceau Rio – Parc Monceau in Paris.
ERYTECH Pharma attends Bio€quity 2013 on May 22 and 23, 2013 in Stockholm, Sweden.
ERYTECH Pharma attends BIO International Convention in Chicago, USA, from April 22 to 25.